Absence of Chest Pain Predicts Severe Pediatric Myocarditis Risk

Navigating the Heterogeneous Spectrum of Pediatric Myocarditis

Pediatric acute myocarditis remains a diagnostic challenge for clinicians due to its highly variable clinical presentation, ranging from mild constitutional symptoms to sudden cardiac death [1, 2]. While the condition is less common than in adults, the emergence of multisystem inflammatory syndrome in children and other post-viral complications has heightened the need for precise cardiac monitoring in the pediatric population [3, 4]. Current management focuses on supporting left ventricular function and mitigating inflammatory damage, yet identifying which children will progress to fulminant heart failure remains difficult [5, 6]. Standardized guidelines emphasize the importance of early risk stratification to prevent long-term morbidity and the need for advanced cardiac interventions [7, 8]. A recent retrospective study offers fresh insights into the specific clinical phenotypes and laboratory markers that distinguish benign cases from those requiring intensive care, providing actionable data for frontline triage.

Post-Pandemic Trends and Cohort Characteristics

The researchers conducted a retrospective cohort study of 38 children admitted to a tertiary center with acute myocarditis between 2012 and 2024. A significant temporal shift in disease incidence emerged, with 76% of the 38 myocarditis diagnoses occurring after 2020. This marked increase in post-pandemic cases highlights a growing clinical burden for pediatricians and emergency physicians. The median age of the patient cohort was 12.5 years, underscoring the vulnerability of the adolescent population to these cardiac events. Among the infectious agents identified, Parvovirus B19 was the most frequently detected pathogen in the post-2020 period, pointing to a dominant viral etiology that should remain high on the differential diagnosis for recent cases. To isolate specific predictors of severe disease, the study compared patients requiring intensive care unit admission with those safely managed in standard pediatric wards. The researchers analyzed the data using nonparametric tests (statistical methods ideal for small or skewed clinical samples that do not follow a normal bell curve) alongside effect size calculations to measure the true clinical magnitude of differences between the two groups. This approach allowed the authors to pinpoint objective risk factors, equipping physicians with reliable markers to guide early triage and resource allocation.

Differentiating the Infarct-Like and Shock Phenotypes

The findings revealed two distinct clinical phenotypes that define the presentation of pediatric myocarditis. The most prevalent phenotype, observed in 59% of the 38 cases, involved patients presenting with chest pain. This 'infarct-like' presentation, which mimics acute myocardial ischemia, was paradoxically associated with a milder clinical course in older children. These patients were generally stable enough for management in standard pediatric wards. In stark contrast, a critically ill subset representing 15% of the cohort presented with cardiogenic shock (a state of severe pump failure resulting in inadequate systemic tissue perfusion). Crucially, the absence of reported chest pain served as a powerful predictor of severe disease, strongly correlating with the need for intensive care unit admission (P < 0.001). These severe cases frequently occurred in younger patients who were developmentally unable to articulate chest discomfort, a silent presentation that severely complicates early triage. For the practicing clinician, the lack of localized pain in a lethargic or symptomatic infant must be treated as a high-risk indicator rather than a reassuring sign. Beyond the absence of pain, objective signs of hemodynamic instability (such as hypotension and poor peripheral perfusion) and a lower left ventricular ejection fraction (a core echocardiographic measure of the heart's pumping efficiency) were critical markers of severity, both reaching statistical significance at P < 0.001. This indicates that younger, nonverbal patients often arrive with advanced hemodynamic stress, requiring rapid escalation of care.

Hemodynamic and Inflammatory Predictors of ICU Admission

Identifying patients at risk for rapid deterioration is the cornerstone of managing pediatric myocarditis. While clinical signs like hemodynamic instability and reduced ejection fraction are clear triggers for escalation, objective laboratory biomarkers provide an essential secondary layer of risk stratification. The study demonstrated that higher levels of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), a well-established biomarker released in response to cardiac wall stress, were significantly associated with severe disease (P = 0.005). These severe cases were defined by profound hemodynamic stress, including clinical shock and elevated NT-pro-BNP, signaling critical myocardial strain and impending pump failure. Alongside markers of direct cardiac stress, systemic inflammatory signals proved highly predictive of poor clinical outcomes. Specifically, elevated procalcitonin (a peptide typically used to detect bacterial infection but also a broad marker of severe systemic inflammation) was associated with severe disease (P = 0.02). The presence of systemic inflammation, marked by elevated procalcitonin, suggests that a hyperactive immune response may drive the rapid progression toward cardiogenic shock. For the frontline physician, these findings underscore the necessity of a dual-biomarker approach: combining cardiac-specific markers like NT-pro-BNP with inflammatory markers like procalcitonin can help rapidly identify which children require immediate transfer to a pediatric intensive care unit.

References

1. Priori SG, Blomström‐Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2015. doi:10.1093/eurheartj/ehv316

2. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018. doi:10.1016/s0140-6736(18)32203-7

3. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud‐Elsayed H, Dalvi B, Rad EM. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. The Egyptian Heart Journal. 2020. doi:10.1186/s43044-020-00075-z

4. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020. doi:10.1016/j.eclinm.2020.100527

5. Yao Q, Zhan S. Corticosteroid in anti-inflammatory treatment of pediatric acute myocarditis: a systematic review and meta-analysis.. Italian journal of pediatrics. 2023. doi:10.1186/s13052-023-01423-w

6. Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID‐19 and multisystem inflammatory syndrome in children: A systematic review and meta‐analysis. Pediatric Pulmonology. 2021. doi:10.1002/ppul.25245

7. (HRS) AHRS, societies EBTF, (EuSEM) ESOEM, et al. Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). European Heart Journal. 2009. doi:10.1093/eurheartj/ehp298

8. Silvetti MS, Colonna D, Gabbarini F, et al. New Guidelines of Pediatric Cardiac Implantable Electronic Devices: What Is Changing in Clinical Practice?. Journal of Cardiovascular Development and Disease. 2024. doi:10.3390/jcdd11040099